These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
770 related items for PubMed ID: 15220019
1. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Susanna R, Sheu WP, Latin American Glaucoma Society. Clin Ther; 2004 May; 26(5):755-68. PubMed ID: 15220019 [Abstract] [Full Text] [Related]
2. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. Hatanaka M, Grigera DE, Barbosa WL, Jordao M, Susanna R. J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465 [Abstract] [Full Text] [Related]
3. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. Hatanaka M, Reis A, Sano ME, Susanna R. J Glaucoma; 2010 Dec; 19(5):331-5. PubMed ID: 19730119 [Abstract] [Full Text] [Related]
5. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost/Timolol Study Group. Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375 [Abstract] [Full Text] [Related]
6. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568 [Abstract] [Full Text] [Related]
7. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece. Petounis A, Mylopoulos N, Kandarakis A, Andreanos D, Dimitrakoulias N. J Glaucoma; 2001 Aug; 10(4):316-24. PubMed ID: 11558817 [Abstract] [Full Text] [Related]
10. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P. Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241 [Abstract] [Full Text] [Related]
18. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials. Zabriskie N, Netland PA, Brimonidine with Latanoprost Study Groups 1 and 2. Adv Ther; 2003 Jan; 20(2):92-100. PubMed ID: 12836809 [Abstract] [Full Text] [Related]
19. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Janulevicienë I, Harris A, Kagemann L, Siesky B, McCranor L. Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472 [Abstract] [Full Text] [Related]
20. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P. Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448 [Abstract] [Full Text] [Related] Page: [Next] [New Search]